299 related articles for article (PubMed ID: 28923104)
41. A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer.
Nakao A; Kasuya H; Sahin TT; Nomura N; Kanzaki A; Misawa M; Shirota T; Yamada S; Fujii T; Sugimoto H; Shikano T; Nomoto S; Takeda S; Kodera Y; Nishiyama Y
Cancer Gene Ther; 2011 Mar; 18(3):167-75. PubMed ID: 21102422
[TBL] [Abstract][Full Text] [Related]
42. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.
Wrangle JM; Velcheti V; Patel MR; Garrett-Mayer E; Hill EG; Ravenel JG; Miller JS; Farhad M; Anderton K; Lindsey K; Taffaro-Neskey M; Sherman C; Suriano S; Swiderska-Syn M; Sion A; Harris J; Edwards AR; Rytlewski JA; Sanders CM; Yusko EC; Robinson MD; Krieg C; Redmond WL; Egan JO; Rhode PR; Jeng EK; Rock AD; Wong HC; Rubinstein MP
Lancet Oncol; 2018 May; 19(5):694-704. PubMed ID: 29628312
[TBL] [Abstract][Full Text] [Related]
43. Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer.
Bott MJ; Yang SC; Park BJ; Adusumilli PS; Rusch VW; Isbell JM; Downey RJ; Brahmer JR; Battafarano R; Bush E; Chaft J; Forde PM; Jones DR; Broderick SR
J Thorac Cardiovasc Surg; 2019 Jul; 158(1):269-276. PubMed ID: 30718052
[TBL] [Abstract][Full Text] [Related]
44. A phase 1 trial of the safety, tolerability and biological effects of intravenous Enadenotucirev, a novel oncolytic virus, in combination with chemoradiotherapy in locally advanced rectal cancer (CEDAR).
O'Cathail SM; Davis S; Holmes J; Brown R; Fisher K; Seymour L; Adams R; Good J; Sebag-Montefiore D; Maughan T; Hawkins MA
Radiat Oncol; 2020 Jun; 15(1):151. PubMed ID: 32532291
[TBL] [Abstract][Full Text] [Related]
45. A Phase 1 Trial of Oncolytic Adenovirus ICOVIR-5 Administered Intravenously to Cutaneous and Uveal Melanoma Patients.
García M; Moreno R; Gil-Martin M; Cascallò M; de Olza MO; Cuadra C; Piulats JM; Navarro V; Domenech M; Alemany R; Salazar R
Hum Gene Ther; 2019 Mar; 30(3):352-364. PubMed ID: 30234393
[TBL] [Abstract][Full Text] [Related]
46. Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients.
Adair RA; Roulstone V; Scott KJ; Morgan R; Nuovo GJ; Fuller M; Beirne D; West EJ; Jennings VA; Rose A; Kyula J; Fraser S; Dave R; Anthoney DA; Merrick A; Prestwich R; Aldouri A; Donnelly O; Pandha H; Coffey M; Selby P; Vile R; Toogood G; Harrington K; Melcher AA
Sci Transl Med; 2012 Jun; 4(138):138ra77. PubMed ID: 22700953
[TBL] [Abstract][Full Text] [Related]
47. Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer.
Sebastian M; Papachristofilou A; Weiss C; Früh M; Cathomas R; Hilbe W; Wehler T; Rippin G; Koch SD; Scheel B; Fotin-Mleczek M; Heidenreich R; Kallen KJ; Gnad-Vogt U; Zippelius A
BMC Cancer; 2014 Oct; 14():748. PubMed ID: 25288198
[TBL] [Abstract][Full Text] [Related]
48. Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.
Su BH; Shieh GS; Tseng YL; Shiau AL; Wu CL
Oncotarget; 2015 Nov; 6(35):38308-26. PubMed ID: 26515462
[TBL] [Abstract][Full Text] [Related]
49. PolySia-Specific Retargeting of Oncolytic Viruses Triggers Tumor-Specific Immune Responses and Facilitates Therapy of Disseminated Lung Cancer.
Kloos A; Woller N; Gürlevik E; Ureche CI; Niemann J; Armbrecht N; Martin NT; Geffers R; Manns MP; Gerardy-Schahn R; Kühnel F
Cancer Immunol Res; 2015 Jul; 3(7):751-63. PubMed ID: 25701327
[TBL] [Abstract][Full Text] [Related]
50. Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: first clinical experience and evidence of an immune response.
Rüttinger D; van den Engel NK; Winter H; Schlemmer M; Pohla H; Grützner S; Wagner B; Schendel DJ; Fox BA; Jauch KW; Hatz RA
J Transl Med; 2007 Sep; 5():43. PubMed ID: 17868452
[TBL] [Abstract][Full Text] [Related]
51. [Abscopal effect on metastatic tumor induced by oncolytic virus of H101 combining with local heating].
Hu F; Hu XH; Yu P; Zhang JX; Lou GG; Liu HL; Wu B; Zhao RH; Xia HQ; Wang Y; Chen J; Ben Y; Chen SY
Ai Zheng; 2006 Aug; 25(8):919-24. PubMed ID: 16965669
[TBL] [Abstract][Full Text] [Related]
52. Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features.
Rudin CM; Poirier JT; Senzer NN; Stephenson J; Loesch D; Burroughs KD; Reddy PS; Hann CL; Hallenbeck PL
Clin Cancer Res; 2011 Feb; 17(4):888-95. PubMed ID: 21304001
[TBL] [Abstract][Full Text] [Related]
53. Oncolytic virotherapy for small-cell lung cancer induces immune infiltration and prolongs survival.
Kellish P; Shabashvili D; Rahman MM; Nawab A; Guijarro MV; Zhang M; Cao C; Moussatche N; Boyle T; Antonia S; Reinhard M; Hartzell C; Jantz M; Mehta HJ; McFadden G; Kaye FJ; Zajac-Kaye M
J Clin Invest; 2019 Apr; 129(6):2279-2292. PubMed ID: 31033480
[TBL] [Abstract][Full Text] [Related]
54. Vitamin D3-inducible mesenchymal stem cell-based delivery of conditionally replicating adenoviruses effectively targets renal cell carcinoma and inhibits tumor growth.
Hsiao WC; Sung SY; Liao CH; Wu HC; Hsieh CL
Mol Pharm; 2012 May; 9(5):1396-408. PubMed ID: 22480282
[TBL] [Abstract][Full Text] [Related]
55. Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors.
Rudin CM; Pandha HS; Zibelman M; Akerley WL; Harrington KJ; Day D; Hill AG; O'Day SJ; Clay TD; Wright GM; Jennens RR; Gerber DE; Rosenberg JE; Ralph C; Campbell DC; Curti BD; Merchan JR; Ren Y; Schmidt EV; Guttman L; Gupta S
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36669791
[TBL] [Abstract][Full Text] [Related]
56. Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers.
Reddy PS; Burroughs KD; Hales LM; Ganesh S; Jones BH; Idamakanti N; Hay C; Li SS; Skele KL; Vasko AJ; Yang J; Watkins DN; Rudin CM; Hallenbeck PL
J Natl Cancer Inst; 2007 Nov; 99(21):1623-33. PubMed ID: 17971529
[TBL] [Abstract][Full Text] [Related]
57. Immunotherapy for thoracic oncology gone viral.
Patel MR
Immunotherapy; 2018 Apr; 10(5):383-390. PubMed ID: 29473469
[TBL] [Abstract][Full Text] [Related]
58. Viral genome DNA/lipoplexes elicit in situ oncolytic viral replication and potent antitumor efficacy via systemic delivery.
Kwon OJ; Kang E; Kim S; Yun CO
J Control Release; 2011 Oct; 155(2):317-25. PubMed ID: 21699929
[TBL] [Abstract][Full Text] [Related]
59. Activity of a group B oncolytic adenovirus (ColoAd1) in whole human blood.
Di Y; Seymour L; Fisher K
Gene Ther; 2014 Apr; 21(4):440-3. PubMed ID: 24553347
[TBL] [Abstract][Full Text] [Related]
60. Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02).
Diab A; Tannir NM; Bentebibel SE; Hwu P; Papadimitrakopoulou V; Haymaker C; Kluger HM; Gettinger SN; Sznol M; Tykodi SS; Curti BD; Tagliaferri MA; Zalevsky J; Hannah AL; Hoch U; Aung S; Fanton C; Rizwan A; Iacucci E; Liao Y; Bernatchez C; Hurwitz ME; Cho DC
Cancer Discov; 2020 Aug; 10(8):1158-1173. PubMed ID: 32439653
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]